MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

Home・Akcijų sąrašas・Fate Therapeutics Inc

Fate Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

1.39 2.96

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.38

Max

1.3900000000000001

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-124K -32M
Pardavimai	-372K 1.4M
Pelnas, tenkantis vienai akcijai	-0.27
Pelno marža	-2,364.792
Darbuotojai	161
EBITDA	-13M -42M

Rekomendacijos
By TipRanks
Rekomendacijos	Neutralu
12 mėnesių prognozė	+43.88% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-11

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-22M 152M
Ankstesnė atidarymo kaina	-1.57
Ankstesnė uždarymo kaina	1.39

Naujienos nuotaikos

By Acuity

34%

66%

110 / 348 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

0.9101 / 1.14 Palaikymas ir pasipriešinimas

Fate Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-17 20:26; UTC

Įsigijimai, susijungimai, perėmimai

UCB to Buy Neurona Therapeutics for Up to $1.15 Billion

2026-04-17 18:15; UTC

Svarbiausios naujienos

Fed's Waller: Prolonged Iran Conflict Could Block Path to Rate Cuts

2026-04-17 16:49; UTC

Svarbiausios naujienos

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

2026-04-17 16:49; UTC

Svarbiausios naujienos

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI Data Due as Focus Remains on Middle East

2026-04-17 22:58; UTC

Uždarbis

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

2026-04-17 21:32; UTC

Rinkos pokalbiai

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

2026-04-17 21:22; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-04-17 21:22; UTC

Rinkos pokalbiai

Moody's Downgrades Belgium to A1 -- Market Talk

2026-04-17 20:52; UTC

Uždarbis

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

2026-04-17 20:50; UTC

Rinkos pokalbiai

Uždarbis

Įsigijimai, susijungimai, perėmimai

Tech, Media & Telecom Roundup: Market Talk

2026-04-17 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-04-17 20:29; UTC

Uždarbis

These Stocks Are Today's Movers: Royal Caribbean, Dow Inc., Netflix, Intel, Albemarle, Autoliv, Alcoa, and More -- Barrons.com

2026-04-17 20:11; UTC

Įsigijimai, susijungimai, perėmimai

UCB to Buy Neurona Therapeutics for Up to $1.15B

2026-04-17 19:34; UTC

Rinkos pokalbiai

Uždarbis

Įsigijimai, susijungimai, perėmimai

Global Equities Roundup: Market Talk

2026-04-17 19:34; UTC

Rinkos pokalbiai

Uždarbis

Įsigijimai, susijungimai, perėmimai

Analysts See Netflix's Deal Commentary as Notable -- Market Talk

2026-04-17 19:31; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Futures Fall on Reopening of Strait of Hormuz -- Market Talk

2026-04-17 19:26; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Edge Up -- Market Talk

2026-04-17 19:21; UTC

Rinkos pokalbiai

Albemarle's Outperformance Belies Longer-Term Risks -- Market Talk

2026-04-17 19:15; UTC

Rinkos pokalbiai

Danaher Seen Rebounding in 2H After Tools-Sector Weakness -- Market Talk

2026-04-17 19:07; UTC

Rinkos pokalbiai

Danaher Faces Tough Comparative but Long‑Term Story Intact -- Market Talk

2026-04-17 18:57; UTC

Svarbiausios naujienos

U.S. Stocks Surge on Hope Iran War Nearing End. Foreign Leaders Have a More Sober View. -- Barrons.com

2026-04-17 18:53; UTC

Įsigijimai, susijungimai, perėmimai

UCB Expects 2026 Adjusted Ebitda Growth in High Single-Digit to Mid-Teens Percentage Range at Constant Exchange Rates

2026-04-17 18:53; UTC

Įsigijimai, susijungimai, perėmimai

UCB 2026 Rev Guidance Unchanged

2026-04-17 18:52; UTC

Įsigijimai, susijungimai, perėmimai

UCB: Neurona Deal to Include $650M Upfront and Up to $500M in Potential Future Milestones

2026-04-17 18:52; UTC

Įsigijimai, susijungimai, perėmimai

UCB to Acquire Neurona Therapeutics for Up to $1.15B Including Potential Milestones

2026-04-17 18:14; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Precious Metals Close Higher as Stronger Demand Eyed -- Market Talk

2026-04-17 18:00; UTC

Svarbiausios naujienos

Fed's Waller: Quick Resolution in Middle East Could Allow Cuts Later This Year

2026-04-17 18:00; UTC

Svarbiausios naujienos

Fed's Waller: Job Losses May Not Signal Recession Amid Demographic Changes

2026-04-17 17:31; UTC

Rinkos pokalbiai

Svarbiausios naujienos

U.S. Oil Rig Count Down By 1 at 410 -- Market Talk

2026-04-17 17:26; UTC

Rinkos pokalbiai

Uždarbis

Netflix's Ability to Grow Engagement Seen as Up in the Air -- Market Talk

Akcijų palyginimas

Kainos pokytis

Fate Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

43.88% į viršų

12 mėnesių prognozė

Vidutinis 2 USD 43.88%

Aukščiausias 2 USD

Žemiausias 2 USD

Remiantis 3 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Fate Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

3 ratings

Pirkti

Laikyti

Parduoti

Remiantis 3 analitikų, pateikusių Fate Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

0.9101 / 1.14Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Rinkos nuotaikos

By Acuity

110 / 348 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.